Literature DB >> 7525964

Evaluation of laboratory methods for cystic fibrosis carrier screening: reliability, sensitivity, specificity, and costs.

Z H Miedzybrodzka1, Z Yin, K F Kelly, N E Haites.   

Abstract

We report a comparative evaluation of three different laboratory methods for screening large numbers of mouthwash DNA samples for common cystic fibrosis mutations. Sensitivity, specificity, and costs of ARMS (allele refractory mutation detection system), dot blotting, and a deletion/digest/PAGE method (multiplex PCR of exons 10 and 11, digest with HincII followed by polyacrylamide gel electrophoresis (PAGE)) were assessed. ARMS was the most reliable and sensitive method and so was considered more suitable than the cheaper deletion/digest/PAGE. As well as being less reliable than ARMS, the dot blotting method assessed was considerably more costly. ARMS was the best laboratory method for CF screening tested.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7525964      PMCID: PMC1049977          DOI: 10.1136/jmg.31.7.545

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  16 in total

1.  Identification of the cystic fibrosis gene: genetic analysis.

Authors:  B Kerem; J M Rommens; J A Buchanan; D Markiewicz; T K Cox; A Chakravarti; M Buchwald; L C Tsui
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

2.  Analysis of human Y-chromosome-specific reiterated DNA in chromosome variants.

Authors:  L M Kunkel; K D Smith; S H Boyer; D S Borgaonkar; S S Wachtel; O J Miller; W R Breg; H W Jones; J M Rary
Journal:  Proc Natl Acad Sci U S A       Date:  1977-03       Impact factor: 11.205

3.  Simple non-invasive method to obtain DNA for gene analysis.

Authors:  N Lench; P Stanier; R Williamson
Journal:  Lancet       Date:  1988-06-18       Impact factor: 79.321

4.  Antenatal cystic fibrosis carrier screening--whether, when and how?

Authors:  Z Miedzybrodzka; N Haites; M Hall; A Templeton; T Marteau; J Dean; K Kelly; I Russell
Journal:  Paediatr Perinat Epidemiol       Date:  1993-10       Impact factor: 3.980

5.  Prevalence of cystic fibrosis mutations in the Grampian region of Scotland.

Authors:  Z H Miedzybrodzka; J C Dean; G Russell; J A Friend; K F Kelly; N E Haites
Journal:  J Med Genet       Date:  1993-04       Impact factor: 6.318

6.  Three point mutations in the CFTR gene in French cystic fibrosis patients: identification by denaturing gradient gel electrophoresis.

Authors:  M Vidaud; P Fanen; J Martin; N Ghanem; S Nicolas; M Goossens
Journal:  Hum Genet       Date:  1990-09       Impact factor: 4.132

7.  A cluster of cystic fibrosis mutations in the first nucleotide-binding fold of the cystic fibrosis conductance regulator protein.

Authors:  G R Cutting; L M Kasch; B J Rosenstein; J Zielenski; L C Tsui; S E Antonarakis; H H Kazazian
Journal:  Nature       Date:  1990-07-26       Impact factor: 49.962

8.  Nearly 80% of cystic fibrosis heterozygotes and 64% of couples at risk may be detected through a unique screening of four mutations by ASO reverse dot blot.

Authors:  J L Serre; A Taillandier; E Mornet; B Simon-Bouy; J Boué; A Boué
Journal:  Genomics       Date:  1991-12       Impact factor: 5.736

9.  Prenatal screening for cystic fibrosis.

Authors:  M E Mennie; A Gilfillan; M Compton; L Curtis; W A Liston; I Pullen; D A Whyte; D J Brock
Journal:  Lancet       Date:  1992-07-25       Impact factor: 79.321

10.  Development, multiplexing, and application of ARMS tests for common mutations in the CFTR gene.

Authors:  R M Ferrie; M J Schwarz; N H Robertson; S Vaudin; M Super; G Malone; S Little
Journal:  Am J Hum Genet       Date:  1992-08       Impact factor: 11.025

View more
  2 in total

1.  Genetic testing in the European Union: does economic evaluation matter?

Authors:  Fernando Antoñanzas; R Rodríguez-Ibeas; M F Hutter; R Lorente; C Juárez; M Pinillos
Journal:  Eur J Health Econ       Date:  2011-05-20

2.  Cost effectiveness of antenatal screening for cystic fibrosis.

Authors:  H S Cuckle; G A Richardson; T A Sheldon; P Quirke
Journal:  BMJ       Date:  1995-12-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.